CliffBio
small molecule

SENSORCAINE

BUPIVACAINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameSENSORCAINE
Active ingredientBUPIVACAINE HYDROCHLORIDE
Strength0.75%
Dosage formINJECTABLE
RouteSPINAL
ModalitySmall molecule
FDA approvalApril 1987
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.